Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

202.08 +1.20 (+0.60%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
74 75 Next >
High-yield, deep-value AbbVie fell off the patent cliff and lived
AbbVie's deep value and high yield attract income investors, and the patent cliff worry lessens daily. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
AbbVie Stock Slips As Humira Struggles Continue, But Drugmaker Raises Outlook
Humira sales continued to decline amid a battle with new biosimilars in the U.S. 
Via Investor's Business Daily
Earnings Scheduled For October 27, 2023
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is projected to report quarterly earnings at $2.26 per share on revenue of $12.56 billion. 
Via Benzinga
Earnings Outlook For AbbVie
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
The market has punished them, but don't overlook these stocks. 
Via The Motley Fool
The 7 Best Forever Stocks to Buy for October 2023
These forever stocks have held up incredibly well despite the economic troubles offering healthy upside compared to its peers. 
Via InvestorPlace
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at... 
Via Talk Markets
Topics Economy
Exposures Economy
7 Dividend Stocks to Buy and Hold Forever and Ever
Investors must consider long-term dividend stocks to buy for their safety as markets remain turbulent in mid-October. 
Via InvestorPlace
Is AbbVie Stock Too Pricey to Touch Right Now?
Other pharmaceutical companies are trading for far lower multiples. 
Via The Motley Fool
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Looking Into AbbVie's Recent Short Interest
Via Benzinga
Looking At AbbVie's Recent Unusual Options Activity
Via Benzinga
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
7 Dividend Aristocrats to Batten Down the Hatches
With uncertainty clouding the capital market ecosystem, investors may take confidence with these dividend aristocrats. 
Via InvestorPlace
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
Investors wonder if the healthcare giant can keep raising its payout now that it no longer sells the consumer health brands that made it famous. 
Via The Motley Fool
Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets
In the week ahead, earnings season moves into full swing with reports from companies like Microsoft, Alphabet, Meta Platforms and Amazon. 
Via Benzinga
Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners
Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF). 
Via Benzinga
Is the "New" Johnson & Johnson Stock a Buy With Its Improved Profit Outlook?
Some things are different about J&J. But other things remain the same as they've been for a long time. 
Via The Motley Fool
Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine
Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical... 
Via Benzinga
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
These three top-notch stocks would make great additions to any dividend portfolio. 
Via The Motley Fool
Healthcare Portfolio Focus Stocks
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields. 
Via Talk Markets
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update. 
Via Investor's Business Daily
3 Dividend Growth Stocks You Can Buy and Hold Forever
Investors can sit back and let the dividends flow in with these great stocks. 
Via The Motley Fool
7 Dividend Kings to Buy for Royal Returns
These dividend kings earn consistent income from steadily growing payments. Buy these stocks that have risen for 50 years or more. 
Via InvestorPlace
ABBV Stock: Buy for the Yield, Hold for This Other Reason
"Safe harbor" status and a high, growing dividend yield isn't the only thing that's appealing with ABBV stock. 
Via InvestorPlace
Billionaire Paul Tudor Jones Predicts a Recession in Early 2024. Here's What It Could Mean for Stocks.
The successful hedge fund manager hasn't had a perfect record with his economic predictions in recent years. 
Via The Motley Fool
Topics Economy
Exposures Economy
3 Absurdly Cheap Dividend Stocks to Buy and Hold for Years
These stocks are potential bargain buys for investors right now, just waiting to get scooped up. 
Via The Motley Fool
The 3 Best Defensive Stocks for Nervous Investors
The best defensive stocks are especially worth considering at the moment as volatility spikes and confidence wavers. 
Via InvestorPlace
AbbVie Stock Moves Higher With Rising Relative Strength
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue? 
Via Investor's Business Daily
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.